Objective-Rupture of atherosclerotic plaques is the major cause of acute coronary events (CEs). Plaque destabilization is the consequence of an imbalance between inflammatory-driven degradation of fibrous tissue and smooth muscle celldependent tissue repair. Proinflammatory factors have been documented extensively as biomarkers of cardiovascular risk but factors that contribute to stabilization of atherosclerotic plaques have received less attention. The present study aimed to investigate whether plasma levels of the smooth muscle cell growth factor epidermal growth factor (EGF), heparinbinding-EGF (HB-EGF), and platelet-derived growth factor correlate with plaque phenotype and incidence of CEs. Approach and Results-HB-EGF, EGF and platelet-derived growth factor were measured in plasma from 202 patients undergoing carotid endarterectomy and in 384 incident CE cases and 409 matched controls recruited from the Malmö Diet and Cancer cohort. Significant positive associations were found between the plasma levels of all 3 growth factors and the collagen and elastin contents of the removed plaques. CE cases in the Malmö Diet and Cancer cohort had lower levels of HB-EGF in plasma, whereas no significant differences were found for EGF and platelet-derived growth factor. After adjusting for cardiovascular risk factors in a Cox proportional hazard model, the hazard ratio for the highest HB-EGF tertile was 0.61 (95% confidence interval, 0.47-0.82; P<0.001). Conclusions-The associations between high levels of smooth muscle cell growth factors in plasma and a more fibrous plaque phenotype as well as the association between low levels of HB-EGF and incident CEs point to a potential clinically important role for factors that contribute to plaque stabilization by stimulating smooth muscle cells. (Arterioscler Thromb Vasc Biol. 2015;35:222-228. The online-only Data Supplement is available with this article at http://atvb.ahajournals.org/lookup/suppl/
M ost acute cardiovascular events are caused by rupture of an atherosclerotic plaque. 1 Plaque rupture is the consequence of a local imbalance between an inflammatorydriven degradation of the fibrous tissue and smooth muscle cell (SMC)-dependent tissue repair. 2 Rupture-prone plaques (also referred to as vulnerable plaques or thin-cap atheromas) are characterized by large extracellular lipid deposits, inflammation, and necrosis as well as by a reduced content of SMC and connective tissue proteins. 1, 2 It is well documented that increased plasma levels of inflammatory markers are associated with a higher cardiovascular risk. 3, 4 However, the possibility that the low plasma levels of factors stimulating SMC repair responses also may predict cardiovascular risk has to date received little attention.
Medial SMCs dedifferentiate into a synthetic phenotype and migrate into the arterial intima to produce extracellular matrix (ECM) proteins that subsequently form a fibrous cap. 5 Plaque inflammation is associated with degradation of this fibrous cap by infiltrating macrophages releasing matrix metalloproteinases (MMPs). 6 Under such conditions, further activation of SMC proliferation and ECM synthesis is necessary to maintain the integrity of the fibrous cap. Epidermal growth factor (EGF), heparin-binding EGF (HB-EGF), and platelet-derived growth factor-B (PDGF) are 3 of the most important factors responsible for stimulating SMC proliferation and ECM synthesis. EGF and HB-EGF are members of the EGF-family. 7 HB-EGF is produced mainly by activated macrophages, 8 endothelial cells, 9 and SMCs, 10 whereas EGF is also secreted by platelets. 11 Both growth factors signal via the EGF receptor, expressed on a variety of cells. 12, 13 The localization of HB-EGF in plaques has suggested a role in promoting migration and proliferation of SMCs as well as in the SMCmacrophage interaction during atherogenesis. 14, 15 PDGF and its receptor, PDGFR, are barely detectable in normal vessels but highly expressed in diseased vessels. 16 PDGF is secreted by platelets, endothelial cells, and macrophages and has been implicated in numerous fibrotic diseases. 17 Several studies have suggested a role for PDGF in promoting neointima formation. Neutralizing PDGF inhibited the migration of SMCs and reduced the neointima size, 18 whereas infusion of PDGF increased intimal thickening after arterial injury in rats. 19 In the present study, we aimed to investigate whether plasma levels of HB-EGF, EGF, and PDGF are associated with a fibrous plaque phenotype and with a lower risk for the development of coronary events (CEs). In a study based on plasma and plaque homogenates from 202 carotid endarterectomy patients, we could demonstrate that there are significant associations between the plasma levels of all 3 growth factors and carotid plaque contents of both collagen and elastin. Moreover, in a prospective nested case-control study involving 384 CE cases and 409 matched noncases we found that subjects with incident CE had lower plasma levels of HB-EGF. Taken together with previous experimental studies, these findings suggest a clinically important role for SMC growth factors in plaque stabilization and protection against development of acute cardiovascular events.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results
To determine whether circulating levels of HB-EGF, EGF, or PDGF correlate with components associated with plaque stability, we used plasma and carotid endarterectomy samples from 202 patients participating in the carotid plaque imaging project (CPIP). One hundred fifteen (56.9%) of the patients had an ipsilateral clinical event (stroke or transient ischemic attack) before surgery, whereas 87 were asymptomatic with a stenosis >80% (Table 1 ). The plasma level of HB-EGF, EGF, or PDGF demonstrated a high level of covariation (r>0.8) and all 3 growth factors demonstrated a significant association with the collagen as well as with the elastin content of the plaques (expressed as mg/g wet weight of the plaque; Table 2 ). Plasma EGF and PDGF correlated inversely with age (r=−0.18; P<0.05 and r=−0.19; P<0.01, respectively), whereas no significant association was observed between HB-EGF and age.
The migration of SMCs from the media into the intima requires the involvement of MMPs, in particular MMP-2 and MMP-9. 20 We observed a positive correlation between the plasma levels of all 3 growth factors and the plaque content of MMP-2, MMP-3, and MMP-10, whereas no associations were observed for MMP-1 or MMP-9 levels ( Table 2) . Moreover, an inverse correlation was observed between HB-EGF, EGF, or PDGF in plasma and plaque caspase 3 activity, indicating a lower grade of apoptosis in plaques from patients with high levels of these growth factors ( Table 2 ; Table I in the online-only Data Supplement). Next, we divided the patients into 2 groups based on growth factor levels (above median for all 3 growth factors [n=80] versus below median for all 3 growth factors [n=78]) and quantified the absolute concentration (pg/mL) in 10 randomly selected patients from each group by luminex. High arbitrary unit in the proximity extension assay correspond to a high concentration of each growth factor in the luminex ( Table II in the online-only Data Supplement). Accordingly, patients who had high levels of all 3 growth factors (n=80) had increased levels of collagen, elastin, MMP2, MMP3, and MMP10 compared with the group which had low levels of the growth factors (n=78; Table II in the online-only Data Supplement). No difference was observed for caspase 3 activity in this analysis ( Table II in the online-only Data Supplement). There were no significant correlation between plasma HB-EGF, EGF, or PDGF and the areas stained for SMC α-actin, neutral lipids (Oil red O), or macrophages (CD68) in plaques ( Table 2 ; Supplements I and II in the online-only Data Supplement). Of note, when analyzing SMC α-actin-stained area at different positions over a separate set of plaques (n=18), we found a 5-fold difference in SMC α-actin-stained area (median %, 17.9 [9.0-24.5] versus 3.6 [1.9-5.2)]) between the section with the highest and the lowest amount of SMC α-actin staining.
These data suggest that the plasma levels of HB-EGF, EGF, and PDGF are associated with a more stable phenotype of carotid plaques in the CPIP cohort. We next asked whether the plasma levels of these growth factors are related to the risk for CE in the general population. To investigate this, we analyzed baseline plasma levels of HB-EGF, EGF, and PDGF in 384 individuals who had a CE during follow-up and 409 controls, matched for age and sex, selected from the Malmö Diet and Cancer (MDC) study cohort (Table 3 and growth factor distribution curves in Figure III in the online-only Data Supplement). There were no significant associations between the plasma levels of HB-EGF, EGF, or PDGF with the white blood cell count, haemoglobinA1c, high-density lipoprotein, and low-density lipoprotein nor systolic or diastolic blood pressure at baseline. There were no significant differences between men and women for any of the 3 growth factors and none of the growth factors demonstrated significant correlations with age in this cohort. Notably, plasma levels of HB-EGF, EGF, and PDGF were markedly lower in the MDC cohort than in the CPIP cohort (Tables 1 and 3 ). CE cases had lower levels of HB-EGF in plasma compared with controls, whereas no significant differences were found for EGF and PDGF ( Table 3 ). The Kaplan-Meier plot of CE-free survival in the study population divided according to baseline HB-EGF tertiles showed that individuals belonging to the highest tertile had the lowest risk for CE (log-rank test P for trend <0.001; Figure) After adjusting for common cardiovascular risk factors (age, sex, diabetes mellitus, smoking habits, systolic blood pressure, and high-density lipoprotein/ low-density lipoprotein ratio) in a Cox proportional hazard model (n=745), the hazard ratio for incident CE in the highest HB-EGF tertile was 0.61 (95% confidence interval, 0.47-0.82; P<0.001; Table 4 ) compared with the lowest tertile. The difference remained significant when analyzing women and men separately.
Discussion
SMCs play a key role in maintaining the stability of atherosclerotic plaques. In the present study, we demonstrate that high plasma levels of the SMC growth factors EGF, HB-EGF, and PDGF are associated with the presence of a more fibrous plaque phenotype as well as with lower caspase 3 activity, indicating less apoptotic cell death in the plaques. These observations suggest that high plasma levels of SMC growth factors are associated with the presence of more stable plaques. In line with this notion, we found that subjects who had a CE during a 15-year follow-up period had significantly lower levels of HB-EGF at the baseline investigation. Also, this association was independent of other established cardiovascular risk factors. Therefore, we foresee 2 major implications for our findings. First, they provide clinical support to a body of experimental studies demonstrating that these growth factors stimulate intimal SMCs, a process of critical importance for maintaining the stability of atherosclerotic plaques. Second, they suggest that plasma levels of SMC growth factors may serve as clinically useful biomarkers for determining cardiovascular risk. For this purpose, these plasma SMC growth factors would likely provide most useful information as part of biomarker panels including both factors associated with inflammatory destabilization of plaques as well as factors contributing to plaque stabilization.
Although all 3 SMC growth factors demonstrated a positive association with plaque content of fibrous proteins, only HB-EGF was found to be independently associated with the incidence of CE, suggesting that this growth factor could be of particular importance in protection against cardiovascular disease (CVD). HB-EGF is a potent mitogen and chemoattractant for SMCs. 8, 12, 13, 21, 22 It is expressed by T cells, 22 macrophages, 8 endothelial cells, 9 and SMCs 10 and stimulates fibroblasts, SMC, and epithelial cells in a para-or autocrine manner. 7 However, unlike other heparin-binding growth factors, HB-EGF is not mitogenic for endothelial cells. 23 Interestingly, HB-EGF has been reported previously to be more potent than EGF and tumor necrosis factor-α in stimulating SMC proliferation and Basic characteristics of the 202 patients operated with carotid endarterectomy included in the carotid plaque imaging project cohort, whose plaque composition was studied. Data are shown as mean±SD, median (interquartile range), or percentage (%) of all patients. Symptomatic, amaurosis fugax, transient ischemic attack or stroke and stenosis >70%. au indicates arbitrary units; BMI, body mass index; EGF, epidermal growth factor; HbA1c, glycosylated hemoglobin A1c; HB-EGF, heparin-binding EGF; HDL, high-density lipoprotein; LDL, low-density lipoprotein; PDGF, platelet-derived growth factor; and WBC, white blood cell counts. Collagen and elastin content was measured biochemically, Concentration of MMPs were measured by multiplex technology and caspase 3 activity was assessed with ELISA in plaque homogenate. The areas positive for αactin, neutral lipids (ORO), and macrophages (CD68) were determined by histochemical stainings. Spearman correlation coefficients between plasma levels of EGF, heparin-binding EGF, and platelet-derived growth factor and plaque components are shown. EGF indicates epidermal growth factor; HB-EGF, heparin-binding EGF; MMP, matrix metalloproteinase; ORO, Oil Red O; and PDGF, platelet-derived growth factor. *P≤0.001; †P≤0.01; and ‡P≤0.05.
migration. The more potent effect of HB-EGF has been proposed to be because of its interaction with cell surface heparin sulfate. 21 Human autopsy studies have suggested that HB-EGF is of importance for vasculogenesis with a high expression by coronary medial SMCs in neonates, infants, and children. 14, 15, 24 The protein is also highly expressed by proliferating SMCs in the neointima after balloon injury of rat carotid. 25 In adult healthy coronary arteries, the expression of HB-EGF by medial SMCs is low but abundant expression is seen in SMC and macrophages in atherosclerotic plaques. 14, 15 Taken together with the present observations, these studies point to a role for HB-EGF in stimulation of arterial SMC growth and migration during vasculogenesis, in response to arterial trauma and in atherosclerotic plaques. It has been reported previously that subjects with severe coronary artery disease have increased plasma levels of HB-EGF, possibly reflecting a high tissue turn over in these lesions. 26 In accordance, we found markedly higher plasma levels of HB-EGF in the carotid endarterectomy patients participating in the CPIP study than in the younger and generally healthier MDC cohort. Although higher levels of HB-EGF in subjects with established CVD may seem to argue against a protective role, it could also reflect the activation of protective repair responses in atherosclerotic vessels. In this context it is interesting to note that lysophosphatidylcholine, which is proinflammatory phospholipid generated in atherosclerotic plaques as a result of lipoprotein phospholipase 2 hydrolysis of oxidized low-density lipoprotein, is a potent inducer of HB-EGF expression. 27 Results from experimental studies, on the role of SMC growth factors in atherosclerosis, have mainly focused on neointima formation after arterial injury rather than their possible role in maintaining the stability of advanced atherosclerotic plaques. Treatment with PDGF was shown to increase neointima formation and inhibition of PDGF with a neutralizing antibody had the opposite effect. 18, 19 Studying the role of PDGF in knockout models has been difficult because of its critical role in embryogenesis. However, a recent study that used transfer of PDGF-deficient embryonic bone marrow cells to investigate the role of PDGF in atherosclerosis demonstrated a delayed formation of the fibrous cap. 28 These findings support a plaque-stabilizing role for PDGF but also suggest that other SMC growth factors might play a role in fibrous cap formation. In line with this notion, we recently demonstrated that in subjects with type 2 diabetes mellitus, symptomatic patients have lower plaque levels of PDGF and collagen than asymptomatic patients. 29 In contrast, Pelisek et al 30 analyzed the amount of PDGF in advanced human carotid artery stenosis and found no significant difference in PDGF levels between symptomatic and asymptomatic plaques.
Plasma levels of EGF, HB-EGF, and PDGF showed significant positive correlations with the plaque content of collagen and elastin. Collagen is the most abundant ECM protein in atherosclerotic plaques and is considered to be important in maintaining the stability of the fibrous cap. 31, 32 Together with elastin, these 2 ECM proteins contribute to elasticity and integrity of the vascular wall in general and of atherosclerotic plaques in particular. The positive association observed between EGF, HB-EGF, and PDGF and ECM proteins indicate that high plasma levels of SMC growth factors might reflect a stable plaque phenotype and suggest that they can function as potential biomarkers for detecting the presence of high-risk plaques. For this purpose, it is interesting to note that the same difference in ECM content was observed when dividing patients based on high or low growth factor levels, further indicating that patients with high levels of all 3 growth factors generally have more fibrous plaques. In accordance, we found that low plasma levels of HB-EGF predicted the incidence of CE in the MDC cohort. As discussed above, HB-EGF, EGF, and PDGF levels seem to be generally higher in subjects with established CVD, which might limit the use of high HB-EGF as a clinically important Basal characteristics of the 793 participants in the prospective nested casecontrol study on the incidence of CE, assessed at baseline. Incident CE occurred in 384 of the participants (CE cases). The 409 age-and sex-matched controls were chosen from the larger MDC cohort. Data are shown as mean±SD, median (interquartile range), or percentage (%) of subjects in each group. au indicates arbitrary units; BP, blood pressure; BMI, body mass index; bulb, bifurcation; CCA, common carotid artery; CE, coronary event; CV, cardiovascular; EGF, epidermal growth factor; HbA1c, glycosylated hemoglobin A1c; HB-EGF, heparin-binding EGF; HDL, high-density lipoprotein; IMT, intima media thickness; LDL, lowdensity lipoprotein; MDC, Malmö Diet and Cancer; PDGF, platelet-derived growth factor; and WBC, white blood cell counts.
Differences between the groups were analyzed using *Mann-Whitney U test for continuous parameters or †χ 2 test for categorical data.
‡P≤0.05; §P≤0.001; and ║P≤0.01.
parameter. This suggests that healthy individuals and patients with known CVD might need to be separately considered when assessing the value of these factors for cardiovascular risk assessment. To what extent this will limit the usefulness of SMC growth factors as biomarkers of CVD risk remains to be fully clarified. It should be emphasized that the present study is primary an association study and the main purpose is to support biological relationships. Previous studies have reported that a high degree of apoptosis is associated with plaque vulnerability. [33] [34] [35] In the present study, we observed an inverse association between plasma levels of HB-EGF, EGF, and PDGF and plaque apoptosis, as assessed by caspase 3 activity, in plaque homogenate. Our findings support the notion that the plaque-stabilizing effects of HB-EGF, EGF, and PDGF may be of clinical relevance in CVD. MMPs contribute to plaque vulnerability by degradation of the plaque ECM. However, some MMPs are also of importance in tissue repair. PDGF stimulates the production of MMP-2 by SMCs and enable the migration of medial SMCs into the intima. 20, 36 Moreover, MMP-2 has been associated previously with a more stable plaque phenotype, whereas a high expression of MMP-1, MMP-8, and MMP-9 is associated with more vulnerable plaques. 37, 38 MMP3, among other types of proteinases, has been implicated in cleaving pro-HB-EGF to release the mature form of HB-EGF. 39 In the present study, we observed a positive correlation between HB-EGF, EGF, and PDGF in plasma and the concentration of both MMP-2 and MMP-3 in plaque homogenate. However, no associations were detected with MMPs previously more related to plaque vulnerability, that is, MMP-1 or MMP-9.
There are some limitations of the present study that need to be considered. First, we associate plasma growth factor levels to carotid plaque composition and therefore assume that carotid plaques reflect the overall vascular system. CVD is a systemic disease and it has been shown previously by Zhao et al 40 that carotid atherosclerotic plaque composition correlates well to, for example, coronary plaque phenotype. However, most importantly, observational studies like this do not provide mechanistic information. The present findings, including associations between high plasma levels of SMC growth factors and more fibrous plaques as well as the association between HB-EGF and incidence of CE, should not be taken as evidence for a functional role of these factors in plaque stabilization. However, they are well in line with a body of experimental evidence demonstrating that they stimulate intimal SMC proliferation and migration, processes generally accepted as important for maintaining plaque stability. Another limitation is that although we found highly significant associations between plasma SMC growth factors and the plaque content of fibrous proteins, we did not observe any positive association with staining for SMC α-actin in plaque sections. One possible explanation to this is that plaques are highly heterogeneous in structure and the 1-mm section used for immunohistochemical analysis may be less representative of the whole plaque compared with the homogenate. This was confirmed in our study by analyzing SMC α-actin staining at different locations in a separate set of plaques. This revealed a 5-fold difference depending on where in the plaque the section was sampled indicating that plaque homogenate is possibly a better measurement for plaque components. In this context it is interesting to note that a previous study by Hellings et al, 41 in line with our results, could not find any association between SMC α-actin staining and risk for cardiovascular events. Moreover, it might be that HB-EGF, PDGF, and EGF predominantly affect ECM production rather than SMC proliferation in the plaque. It is not possible to conclude whether the SMC growth factors identified in plasma have been generated in the vascular wall and subsequently diffused out into the circulation or whether they have been produced elsewhere. The plasma samples from the MDC cohort have been stored for ≈20 years and it cannot be excluded that this has affected the possibility to accurately perform the growth factor measurement. Accordingly, the possibility that the lower growth factor levels detected in the MDC cohort compared with CPIP is explained by a storage artifact needs to be considered Associations between tertiles of HB-EGF and incident CE in cases and controls were calculated using Cox proportional hazard regression adjusted for smoking habits, age, sex, low-density lipoprotein/high-density lipoprotein ratio, systolic blood pressure, diabetes mellitus, and body mass index. Tertile 1 contains the lowest HB-EGF levels. Data are shown as HR (95% CI) using the lowest tertile (first tertile) as reference value (n=745). au indicates arbitrary units; CI, confidence interval; CE, coronary event; HB-EGF, heparin-binding epidermal growth factor; and HR, hazard ratio. *P≤0.001.
although it is unlikely that this would explain the observed difference between coronary cases and controls.
In conclusion, our observations of associations between high levels of SMC growth factors in plasma and a more fibrous plaque phenotype as well as the association between HB-EGF and incident CE point to a clinically important role for factors that may contribute to plaque stabilization by stimulating SMCs. The possibility to use such biomarkers of cardiovascular risk needs to be further evaluated in large prospective studies.
